Evidence map›Paper›PMID 34263337›Full record

ArticleCancer chemotherapy and pharmacology2021

Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma.

Daniel L Gustafson, Keagan P Collins, Jared S Fowles, E J Ehrhart, Kristen M Weishaar, Sunetra Das, Dawn L Duval, Douglas H Thamm

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Daniel L GustafsonFlint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA. Daniel.Gustafson@colostate.edu.ORCID 0000-0002-3063-1669
Keagan P CollinsFlint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.
Jared S FowlesFlint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-7614-5447
E J EhrhartFlint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.
Kristen M WeishaarFlint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0003-2827-2246
Sunetra DasFlint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-8941-1468
Dawn L DuvalFlint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-5310-0078
Douglas H ThammFlint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-8914-7767
Colorado State University · USUniversity of Colorado Cancer Center · US

Funding

Morris Animal Foundation D16CA-003
6 · The paper itself

Abstract

backgroundThis study is a prospective clinical trial in dogs with osteosarcoma testing a gene expression model (GEM) predicting the chemosensitivity of tumors to carboplatin (CARBO) or doxorubicin (DOX) developed using the COXEN method. PATIENTS AND

methodsSixty dogs with appendicular osteosarcoma were enrolled in this trial. RNA isolation and gene expression profiling were conducted with 2 biopsies for 54/63 screened tumors, and with a single biopsy for 9 tumors. Resulting gene expression data were used for calculation of a COXEN score for CARBO and DOX based on a previous study showing the significance of this predictor on patient outcome utilizing retrospective data (BMC Bioinformatics 17:93). Dogs were assigned adjuvant CARBO, DOX or the combination based on the results of the COXEN score following surgical removal of the tumor via amputation and were monitored for disease progression by chest radiograph every 2 months.

resultsThe COXEN predictor of chemosensitivity to CARBO or DOX was not a significant predictor of progression-free interval or overall survival for the trial participants. The calculation of DOX COXEN score using gene expression data from two independent biopsies of the same tumor were highly correlated (P < 0.0001), whereas the calculated CARBO COXEN score was not (P = 0.3039).

conclusionThe COXEN predictor of chemosensitivity to CARBO or DOX is not a significant predictor of outcome when utilized in this prospective study. This trial represents the first prospective trial of a GEM predictor of chemosensitivity and establishes pet dogs with cancer as viable surrogates for prospective trials of prognostic indicators.

Indexed as

Bone NeoplasmsCarboplatinDoxorubicinOsteosarcomaAmputation, SurgicalAnimalsAntineoplastic AgentsCombined Modality TherapyDisease ProgressionDog DiseasesDogsFemaleGene Expression Regulation, NeoplasticMaleProgression-Free SurvivalProspective StudiesAntineoplastic AgentsCarboplatinDoxorubicinBoneCanineCarboplatinCOXENDoxorubicinGene expression

Identifiers

PMID34263337
OpenAlexW3178768303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.